John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 2,822 shares at $7.06 ($20K) on 2022-03-10, disclosed to the SEC on 2022-03-14.
Scheduled sale ($20k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.94 | 822 | $6K | 28.8% |
| 2 | $7.06 | 1,900 | $13K | 67.6% |
| 3 | $7.13 | 100 | $713 | 3.6% |
| Total | $7.03 avg | 2,822 | $20K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |